Skeletal Myosin-Binding Protein C: Defining Function Across Scales Using a Zebrafish Model System.

Myosin-binding protein C (MyBP-C), a thick filament associated protein of vertebrate striated muscle, is a key modulator of muscle contractility. Multiple distinct skeletal muscle MyBP-C isoforms are encoded by two genes in mammals (i.e., MYBPC1 (slow-type) and MYBPC2 (fast-type)) with mutations to these genes now

linked to human skeletal myopathies, such as distal arthrogryposis. In vitro reductionist approaches have proposed mechanisms by which the MyBP-C N terminus modulates muscle contractility through its binding- partner interactions with the actin-thin filament and the myosin head region. Specifically, MyBP-C is believed to

sensitize the thin filament to calcium, stabilize the myosin super-relaxed state, and/or act as a molecular “brake” to slow myofilament sliding. However, since multiple MyBP-C isoforms are co-expressed in mammalian muscle, it has been impossible to define which of these modulatory roles are linked to specific MyBP-C isoforms within

the context of an intact muscle, let alone how they may be altered by genetic mutations. Here we propose a novel approach in zebrafish to generate ‘designer’ muscles exclusively expressing a single, transgene-encoded MyBP-C isoform as desired. Our preliminary data indicate that MyBP-H, an MyBP-C family member, comprises

~95% of myosin binding protein in larval zebrafish swimming muscles. Therefore, Aim 1 makes use of the recently developed CRISPR/Cas9 ‘GeneWeld’ method, to generate precise integration alleles by homology mediated end joining (HMEJ) that will simultaneously: i) interrupt endogenous MyBP-H expression, and; ii) place

a DNA cassette, encoding one of two most functionally extreme MyBP-C isoforms, under regulatory control of the most highly expressed endogenous MyBP gene locus. By this approach, we propose to create zebrafish with “designer MyBP-C” muscles. Quantitative proteomics will enable us to determine whether transgenic MyBP-C

accumulates to wildtype levels, while immunofluorescence of FLAG-tagged transgenic MyBP-C will be used to confirm proper subcellular localization. In Aim 2 we use biophysical assays previously developed in the Warshaw lab to define the functional impact of transgenic MyBP-C isoforms across multiple scales. Specifically, native

myosin thick filaments will be used to assess MyBP-C “braking” action, while myofibrils will be used to assess the presence of the super-relaxed myosin state. Data from these simplified muscle systems obtained from the proposed “designer MyBP-C” zebrafish will be correlated with intact larval muscle mechanics. Thus, this project

will provide significant insight into how an individual MyBP-C isoform modulates both molecular and cellular contractility in the context of intact muscle. This “designer MyBP-C” zebrafish model system will create a platform for future mechanistic studies of MyBP-C mutations associated with human skeletal myopathies as a first step

to therapeutic design.